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Abstract
Background: Intrahepatic cholangiocarcinoma (ICC) is an aggressive, highly lethal tumors and lacks of effective
chemo and targeted therapies. Cell lines and animal models, even partially reflecting tumor characteristics, have
limits to study ICC biology and drug response. In this work, we created and characterized a novel ICC patient-
derived xenograft (PDX) model of Italian origin.
Methods: Seventeen primary ICC tumors derived from Italian patients were implanted into NOD (Non-Obese
Diabetic)/Shi-SCID (severe combined immunodeficient) mice. To verify if the original tumor characteristics were
maintained in PDX, immunohistochemical (cytokeratin 7, 17, 19, and epithelial membrane antigen) molecular (gene
and microRNA expression profiling) and genetic analyses (comparative genomic hybridization array, and mutational
analysis of the kinase domain of EGFR coding sequence, from exons 18 to 21, exons 2 to 4 of K-RAS, exons 2 to 4
of N-RAS, exons 9 and 20 of PI3KCA, and exon 15 of B-RAF) were performed after tumor stabilization.
Results: One out of 17 (5.8 %) tumors successfully engrafted in mice. A high molecular and genetic concordance
between primary tumor (PR) and PDX was confirmed by the evaluation of biliary epithelial markers, tissue
architecture, genetic aberrations (including K-RAS G12D mutation), and transcriptomic and microRNA profiles.
Conclusions: For the first time, we established a new ICC PDX model which reflects the histology and genetic
characteristics of the primary tumor; this model could represent a valuable tool to understand the tumor biology
and the progression of ICC as well as to develop novel therapies for ICC patients.
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Background
Cholangiocarcinoma (CCA) is the most common biliary
tract neoplasm of the biliary tree, classified, according to
its site of origin, as intrahepatic (ICC), perihilar or extra-
hepatic (ECC) cholangiocarcinoma [1, 2]. These subtypes
differ in their biology, clinical-pathological characteris-
tics and management. ICC accounts for approximately
10-15 % of CCA [3, 4], although its incidence is different
worldwide with a higher incidence in Asia (96 per
100,000 in Thailand) [5], but is increasing also in other
geographic regions [6]. Several risk factors of CCA, in-
clude infectious and inflammatory diseases, congenital
conditions, drugs, and toxins. However, recent studies
identified new and emerging risk factors for ICC, occu-
pational and environment-related [7, 8]: the chronic viral
hepatitis, liver cirrhosis-alcohol-related, smoking, obes-
ity, diabetes and asbestos [9–13]. Patients with unresect-
able disease (70-90 %) have a poor prognosis with a
survival of less than 12 months following diagnosis.
The lack of effective therapies prompts to identify alter-
native approaches, based on a deepen molecular know-
ledge. The high throughput techniques, i.e. gene and
microRNA profiling, next generation sequencing (NGS),
exome sequencing, provide huge amount of data and infor-
mation suitable to identify potential drug targets [14, 15].
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Nowadays, pathogenesis and drug response are usually
studied on preclinical models represented by cell lines, pri-
mary cultures, and xenografts.
In particular, xenografts and orthotopic models ob-
tained by CCA cell lines, carcinogen-induced and genet-
ically engineered mouse model for CCA has been
created [16]. In the last years, patient-derived cancer
xenograft (PDX) models have been established by dir-
ectly engrafting surgically resected human tumor tissues
into immune compromised mice. Molecular and genetic
analysis demonstrated that PDXs rely primary tumor
characteristics, making them suitable models to study
pathogenesis and to test anti-cancer drugs activity.
PDXs are established from different cancer types, in-
cluding gastric, breast, ovarian, colon, lung, prostate,
and pancreatic cancers [17–23].
To date, no human CCA models derived from tumor
patients have been developed.
Here, we established and characterized a patient-
derived ICC model derived from a patient of Italian ori-
gin. This model will be helpful either to provide a more
suitable model for preclinical studies or to test drug
efficacy.
Methods
Establishment and characterization of patient derived
xenograft (PDX)
Tumor samples were obtained from Italian patients sub-
jected to surgical resection for ICC. Biological material
was obtained from patients who has signed the informed
consent, following institutional review board-approved
protocols (“PROFILING Protocol, n° 001-IRCC-00 IIS-
10” approved by Comitato Etico Interaziendale of
A.O.U. San Luigi Gonzaga, Orbassano, Torino, Italy).
This institutional study provides molecular genetic ana-
lysis, set up of primary cultures and the creation of PDX
from tumor biological samples (primary tumor, metasta-
sis, tumor cells taken under paracentesis or thoracentesis
procedures, and blood). We have overall implanted 17
fresh tumor specimens from ICC patients, 14 primary
(PR) and 3 recurrent tumors, here named from CHC001
to CHC020.
For PDX establishment, NOD (Non-Obese Diabetic)/
Shi-SCID (severe combined immunodeficient) female
mice (4–6 weeks old) (Charles River Laboratory) were
maintained under sterile conditions in micro-isolator
cages at the animal facilities of IRCCS-Candiolo. All
animal procedures were approved by the Institutional
Ethical Commission for Animal Experimentation
(Fondazione Piemontese per la Ricerca sul Cancro)
and by the Italian Ministry of Health. Mice were sub-
cutaneously grafted with a fragment of 4x4 mm of
representative tumor.
Immunohistochemistry analysis
The expression of biliary markers Cytokeratin (CK) 7,
17, 19, and epithelial membrane antigen (EMA) [24] was
evaluated by immunohistochemical analysis (IHC) to
compare the characteristics of primary and engrafted
tumor. Slides were incubated with primary antibodies
followed by the appropriate secondary antibodies; the re-
action was visualized by DAB (3,3-diaminiobenzidine)
and counterstained with hematoxylin.
Comparative genomic hybridization array
Genomic DNA of PR and its PDX at fourth generation
was extracted from formalin fixed, paraffin embedded
(FFPE) tissues using the QiAmp FFPE DNA mini Kit
(Qiagen). High-resolution oligonucleotide comparative
genomic hybridization (CGH) arrays analysis was per-
formed following standard operating procedures of
Agilent Technologies. One thousand ng of DNA were
digested by a double enzymatic digestion (AluIþRsa I),
fragmented, amplified, and purified. After the quantifi-
cation with Nanodrop, 2 μg of genomic DNA of both
tumor and control from Promega (Human Genomic
DNA Female N 30742202/male N 30993901) were la-
beled with CY5-dCTPs and CY3-dCTP, respectively,
and hybridized on glass arrays (2 X105 K) at 65C° for
40 hours at 20 rpm. Slides were then washed, scanned
on an Agilent 4000C dual laser scanner and images ana-
lyzed with Feature Extraction v10.5 software. Raw txt
files were then loaded into Cytogenomics software for
data processing and visualization.
Gene and microRNA expression analysis
For gene expression analysis (GEP), tissues were homog-
enized by using TissueLyser LT (Qiagen s.r.l. Milano,
Italy) and total RNA (mRNA and microRNA) was ex-
tracted and purified by Absolutely RNA miRNA kit
(Agilent Technologies), following manufacturers’ proto-
cols. Quantitative and qualitative evaluation of total
RNA was performed by Nanodrop and BioAnalyzer, re-
spectively. For GEP analysis, 100 ng of total RNA were
amplified and labeled using Low Input Quick Amp
Labeling Kit, one-color kit (Agilent Technologies). Six
hundred ng of labeled RNA were hybridized on Sure-
Print G3 Human Gene Expression 8x60K v2 glass arrays.
Arrays were scanned and images analyzed by the Feature
Extraction Software from Agilent Technologies (version
10.7); raw data were then processed using the Biocon-
ductor package Limma (Linear models for microarray
analysis). Background correction was performed with
the normexp method with an offset of 50, and quantile
was used for the between-array normalization. The em-
pirical Bayes method was used to compute a moderated
t-statistics.
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For microRNA analysis, 100 ng of total RNA were la-
beled using the miRNA Complete Labeling and Hyb Kit
and hybridized on Human miRNA Microarray Kit Release
16.0, 8x60K. Arrays were scanned and images analyzed by
the Feature Extraction Software from Agilent Technolo-
gies (version 10.7). Raw data elaboration was carried out
with Bioconductor (http://www.bioconductor.org/) [25],
using R statistical language. Background correction was
performed with the normexp method, and quantile was
used for the between-array normalization. External
datasets: GSE26566 and GSE47764 datasets, containing
normal bile duct gene and miRNA expression profiles
respectively, were downloaded from the GEO website
(http://www.ncbi.nlm.nih.gov/geo/). To merge these
raw data to our own, we first averaged the signal at
probe level (for microRNA arrays, performed on two
different versions of Agilent platform) or at gene symbol
level (for gene expression arrays, performed on two dif-
ferent platforms). The obtained matrices were then
merged and normalized with the quantile function. The
LIMMA (LInear Models for Microarray Analysis) pack-
age was used to identify differentially expressed genes/
microRNAs in tumor versus normal samples. The em-
pirical Bayes method was used to compute a moderated
t-statistics [26].
MicroRNA validation by qRT-PCR
MicroRNA of PDX and of a pool of liver normal tissues
was transcribed in cDNA by using TaqMan microRNA
Reverse Transcription Kit (Applied Biosystem) using
specific primers for mir-21, mir-199, mir-200, mir-31,
and for the housekeeping RPL-21. The TaqMan micro-
RNA Assays (with the different fluorescent probes) and
the TaqMan Universal MasterMix NO Amperase UNG
were used to perform the quantitative Real-time PCR.
All the experiments were carried out in triplicate in op-
tical grade 96-well plates. Quantitative analysis was per-
formed by the measurement of Ct values; briefly, to
calculate the relative expression of the target microRNA
normalized to RPL21, the average of target Ct was sub-
tracted from the average of RPL21 Ct(ΔCt). The amount
of target, normalized to an endogenous reference and
relative to a calibrator (fold-change) is given by 2-ΔΔCt
where the calculation of ΔΔCt involves subtraction by
the ΔCt calibrator value (pool of liver normal tissues).
Mutational analysis
Genomic DNA was extracted by using QIAamp DNA
FFPE Mini kit (Qiagen, Milan, Italy) following the manu-
factures’s instructions. For formalin fixed and paraffin em-
bedded (FFPE) tumor the neoplastic area was obtained by
laser microdissection (VSL-337ND-S, Spectra-Physics,
Mountain View, CA). The kinase domain of EGFR coding
sequence, from exons 18 to 21, was amplified by using
primers and nested polymerase chain reaction (PCR) con-
ditions previously described by Lynch and coll [27]. Exons
2 to 4 of K-RAS and N-RAS, exons 9 and 20 of PI3KCA,
exon 15 of B-RAF were amplified by PCR as previously
Table 1 Clinical-pathological characteristics of ICC patients
Tumor Primary/Recurrence HBV-HCV TNM Tumor size K-RAS mutation Smoking status
CHC-001 primary neg p T2b pN0 G2 40 mm KRAS G12A Yes
CHC-002 recurrence HBV pos r pT2b N0 G3 27 mm WT No
CHC-003 primary neg p T2 N1 G2 35 mm WT No
CHC-005 primary neg pT2b pN0 G3 90 mm WT Yes
CHC-006 primary neg pT2N0 G3 NA WT No
CHC-007 primary neg pT4 pN0 G3 70 mm WT No
CHC-009 primary neg pT2b pN0G2-G3 65 mm WT No
CHC-010 primary HCV pos pT2a pN0 G3 80 mm WT No
CHC-011 primary neg pT2b pN0 G3 45 mm WT Yes
CHC012 recurrence neg r pT2b G2 45 mm WT No
CHC013 primary HBV pos pT2a G3 NA WT No
CHC014 primary neg pT3 N1 G3 115 mm WT No
CHC015 primary neg p T2a pN1 G3 100 mm WT No
CHC017 recurrence neg r pT2a pN0 G2 25 mm WT No
CHC018 primary neg pT3 N1 G3 75 mm WT Yes
CHC019 primary neg pT2bN1 G3 15 mm WT No
CHC020 primary neg pT2b pN0 G2 110 mm WT No
F Female, M Male, Neg negative, Pos positive, NA not available
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described [28, 29]. PCR products were then purified using
Wizard® SV Gel and PCR Clean-Up System (Promega,
Italy) and sense and antisense sequences were obtained
using forward and reverse internal primers, respectively.
Each exon was sequenced using the BigDye Terminator
Cycle sequence following the PE Applied Biosystem strat-
egy and Applied Biosystem ABI PRISM3100 DNA
Sequencer (Applied Biosystem, Forster City, CA). Muta-
tions were confirmed performing two independent PCR
amplifications.
Results
Generation and characterization of BTC patient derived
xenografts
ICC tumors obtained from surgery were subcutaneously
implanted into NOD/SCID mice as described in the Ma-
terials and Methods section. Characteristics of tumor pa-
tients were summarized in Table 1. Ten patients were
females and seven males and the age ranged from 44 to
82; 14 out of 17 (82.4 %) tumor specimens were primary
tumors and 3 out of 17 (17.6 %) were recurrences.
Fig. 1 Immunophenotypical tumor features of CHC001 PDX are maintained through serial passages in mice. Cytokeratin 7 (CK7), CK17, CK19 and
EMA staining on CHC001-PDX in fourth generation (right panel) was similar to primitive (CHC001-PR) tumor (left panel). Hematoxylin counterstaining,
magnification 20X
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Only one tumor out of 17 (5.8 %) was successfully
engrafted. It was a primary tumor and was histopatho-
logically classified as pT2b pN0, moderately differenti-
ated (G2) ICC. Tumor sample was also evaluated for the
presence of HBV or HCV markers, resulting negative.
Patient had chronic colecystitis, but did not have liver
cirrhosis or chronic liver disease, primary sclerosing
cholangitis diabetes, obesity.
Primary tumor, named CHC001 PDX, was successfully
engrafted in mice at the first generation after 4 months;
after reaching a volume of 1000 mm3, tumor was
explanted and re-implanted in new mice. Starting from
the second generation, the latency of growth was de-
creased from 4 months to 1 month until the stabilization
obtained at the fourth generation. If cryopreserved in
DMSO 10 % and FBS 90 % in culture medium, it was
able to successfully engraft in mice when re-implanted.
After stabilization, immunohistochemical and molecular
investigations were performed to verify if both features
were retained in the PDX.
Immunohistochemistry analysis for the expression of
Cytokeratin 7, 17, 19 and EMA as well as the Hematox-
illin & Eosin staining [30] showed that PDX retained the
same morphology of PR up to the fourth generation as
well as the same immunoreactivity (Fig. 1).
CGH analysis
The genomic status of PR and of its PDX was assessed
by array CGH technique. As shown in Fig. 2, we found a
concordance between the two samples (r = 0.64 by
Pearson correlation); the number of common chromo-
somal alteration was 24 with 7 gained regions and 17
lost regions; the most statistically significant chromo-
some regions included the loss of the regions in 3p, 5q,
6p, 8p, 9p, 14q, 18q, and the gain of the regions 1p, 2q,
3q, and 12p, 15q, and 20q. Table 2 summarizes the com-
mon aberrant regions.
Further, we revealed that PDX acquired other alter-
ations, in particular the loss of 3p, the entire 4, 6q, the
entire 7, 10p, 11p, 12q, 15q, 17p, 19p, 21q and 22q, and
the gained regions in 5p, 10q, 13q, 15q, and 20q.
To further characterize the PDX model, we selected
genes allocated in the aberrant regions typical of PDX;
considering the first 500 amplified or deleted genes, re-
spectively, we performed Gene Ontology (GO) analysis,
and GO categories are summarized in Additional file 1:
Table S1.
Gene expression profiling
Gene expression analysis was performed on the primi-
tive tumor and on the PDX at the fourth passage. Fig-
ure 3 showed the correlation plot of differentially
expressed genes obtained by Pearson correlation func-
tion; this correlation is very high (r = 0.94), enforcing
that PDX retained primary tumor characteristics. In
order to find the peculiar characteristics of this tumor,
common differentially expressed genes were compared
to six normal bile duct samples, belonging to the cohort
of Andersen and collaborators [14]. Genes list was fil-
tered on adjusted p-value (<0,00001) and the most
Fig. 2 Comparison of chromosomic aberrations in primary tumor (PR) and in its Patient derived xenograft (PDX). In red, the loss regions, in blue
the gain regions
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significant 300 probes were analyzed for Gene Ontol-
ogy; we found that down-regulated genes are involved
in blood coagulation, inflammation response, and in
lipid metabolism; on the contrary, up-regulated genes
globally affected DNA biosynthesis processes, as nu-
cleosome assembly and organization, translation,
underlying that tumor cells are more active rather
than normal cells. Even the high correlation of gene
expression data, we found 63 up-regulated and 276
down-regulated genes altered in PDX versus primary
tumor (Additional file 2: Table S2). Further, we com-
pared differentially expressed genes in PDX with the
list of genes allocated in amplified or deleted regions
found in PDX; 5 up-regulated and 32 down-regulated
genes were found to be overlapped (Additional file 3:
Table S3).
MicroRNA expression profiling
The comparison between PR and its PDX revealed a high
correlation in terms of microRNA expression (r = 0.92 by
Pearson correlation), as shown in Fig. 4. Common
deregulated microRNAs were compared with those
obtained by normal bile duct in a work of Peng et al.
[31]. Row data were filtered with a logFC < or > 0.58
and a p-value of < 0.01. An unsupervised hierarchical
cluster showed the deregulated microRNAs among
primary and PDX tumors compared to normal bile
duct (Fig. 5). Twenty-eight microRNAs (Table 3), of
which 7 down-regulated and 21 up-regulated were se-
lected. Nine out of 28 microRNAs are involved in the
negative or positive regulation of cell cycle, apoptosis,
migration and proliferation, underlying that these pro-
cesses are altered in tumor cells. In order to enforce
these data, we validated the expression of 4 micro-
RNAs by qRT-PCR. As shown in Additional file 4:
Table 2 Common aberrant regions between primary and its
PDX tumor
GAINED
REGIONS
Chr Name Start Stop Aberration Size N° of Probes
Chr 1 794595 15755378 14960791 582
chr2 165884672 239972470 74087806 2499
chr3 132814897 195420586 62605690 1960
chr10 76385906 76844343 458439 19
chr12 322142 33190977 32868841 1192
chr15 59862504 63866586 4004083 152
chr20 60606430 62701643 2095216 123
LOST
REGIONS
Chr Name Start Stop Aberration Size N° of Probes
chr1 246042299 246655416 613118 25
chr3 18852871 32750279 13897409 382
chr4 8003753 8269985 266233 10
chr5 60785924 71460780 10674857 275
chr6 389423 26225376 25835955 858
chr7 73901713 73947170 45458 4
chr7 143425418 143432891 7474 3
chr7 153530377 153586460 56084 3
chr8 176452 22995207 22818758 751
chr8 39237438 39380654 143217 7
chr9 204193 28849141 28644949 888
chr14 63888769 105942876 42054108 1679
chr15 29212452 29253376 40925 4
chr15 34735949 34785082 49134 3
chr18 47738189 78010032 30271844 911
chr19 2936567 3027913 91347 4
chr22 23998465 24040236 41772 4
Fig. 3 Correlation plot of differentially expressed genes of
CHC001PR (primary tumor) and CHC001PDX in fourth generation
Fig. 4 Correlation plot obtained by the microRNA expression values
of primary and PDX tumors
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Table S4, the trend of expression of mir-21, mir-200,
mir-199, and mir-31 is confirmed.
Furthermore, we analyzed if PDX acquired peculiar
characteristics in terms of microRNA expression;
Additional file 5: Table S5 showed that only let-7a-5p,
miR-15b-5p, let-7d-5p, miR-200b-5p were down-regulated
in PDX compared to primary tumor.
Mutational analysis
Mutational analysis of the kinase domain of EGFR
coding sequence, from exons 18 to 21, exons 2,3 and
4 of K-RAS, exons 2,3 and 4 of N-RAS, exons 9 and
20 of PI3KCA, and exon 15 of B-RAF were per-
formed on PR and on PDX. As shown in Fig. 6, only
the sequence of K-RAS exon 2 is mutated (G12D
mutation) in the primary tumor (panel B) and is
maintained in PDX (panel C).
Discussion
Intrahepatic cholangiocarcinoma constitutes the second
most common primary hepatic malignancy with a very
poor prognosis [32, 33]. Thus, the identification of alter-
native therapeutic options is an urgent step to improve
the outcome of these patients. ICC PDX models could
represent an useful tool either to study the disease from
biological and molecular aspects or to investigate re-
sponse to new therapies. Here, we established and char-
acterized, for the first time, an Italian ICC PDX derived
from fresh tumor tissue.
We subcutaneously implanted 17 ICC fresh tumor tis-
sues into immunocompromised mice and we obtained a
rate of successful engraftment of 5.8 % (1/17). The en-
graftment was reached after 4 months from implant,
while for the subsequent generations the latency was sig-
nificantly reduced to one month. The same result was
obtained re-implanting archival frozen tissues.
Fig. 5 Unsupervised hierarchical cluster showed the different pattern of expression between tumors and normal bile duct
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The limited success of engraftment of these tumors is
not clear. For colorectal cancer PDX the engraftment
rate is 67 % [21]; as concerning mammary tumors, the
rate is higher with metastatic tissues rather than primary
tumors; moreover, graft achievement depends on other
factors, as tumor histotypes, grading, and on the pres-
ence of Estrogen and HER2 receptors [34]. We can
speculate that the presence of K-RAS mutation in our
PDX model could be a driver of the more aggressive
phenotype, thus explaining the successful engraftment,
as shown in colorectal cancer PDX model [35].
K-RAS mutations are one of the biological determinants
of anti-EGFR target therapy resistance in colorectal cancer
[36]. Although the role of K-RAS in response to the anti-
EGFR therapy in CCA is controversial [37–39], this model
could be suitable for the evaluation of the effectiveness of
alternative therapies in K-RAS mutated patients for whom
anti- EGFR therapies are unfit.
We further compared immunophenotypical and mo-
lecular features of PR with its corresponding PDX and we
Table 3 Common differentially expressed microRNAs obtained
by the comparison of tumors (primary and PDX) with normal
bile duct
miR name logFC P.Value Function
hsa-miR-142-3p -1.14661 0.0049146
hsa-miR-199a-3p -1.09606 0.0019647 Tumor suppressor
hsa-miR-199a-5p -0.79526 0.0013074
hsa-miR-199b-5p -0.76865 0.0030379
hsa-miR-148a-3p -0.75023 0.0008472
hsa-miR-150-5p -0.68957 0.000765 Migration/invasion
hsa-miR-23a-3p -0.66533 0.0002675
hsa-miR-338-3p 0.767824 0.0037119 Proliferation
hsa-miR-222-3p 0.805174 0.0021683 Proliferation/invasion
hsa-miR-24-3p 0.828359 0.0002201 Proliferation/apoptosis
hsa-miR-92a-3p 0.853479 0.0053925
hsa-miR-106b-5p 0.878651 0.0057063
hsa-miR-130a-3p 0.92218 0.0052659
hsa-miR-16-5p 1.074798 0.0088751
hsa-miR-31-3p 1.075722 0.0051418
hsa-miR-20a-5p 1.089514 0.0034313
hsa-miR-1260a 1.191454 0.0081444
hsa-miR-193b-3p 1.222449 0.0002997 Tumor suppressor
hsa-miR-21-3p 1.236425 0.0045017 Oncogene
hsa-miR-17-5p 1.326209 0.0009174
hsa-miR-30a-5p 1.417434 0.0032646 Proliferation/migration
hsa-miR-200c-3p 1.502242 0.0011469 EMT-Transition
hsa-let-7b-5p 1.688168 0.0007466 Proliferation/apoptosis
hsa-miR-210-3p 2.014905 0.0002827
hsa-miR-31-5p 2.277681 9.30E-05 Cell cycle
hsa-miR-141-3p 2.387609 0.0065583
hsa-miR-720-v18.0 2.440588 0.0085144
Fig. 6 Electropherograms of K-RAS (exon 2). Wilde type sequence of
K-RAS exon 2 (a), K-RAS G12A mutations found in CHC001 PR (primary
tumors) (b) and CHC001 PDX in fourth generation (c)
Cavalloni et al. BMC Cancer  (2016) 16:90 Page 8 of 11
found that both tissue architecture and immunoreactivity
of biliary epithelial markers were maintained in PDX.
The genetic relationship between PR and its PDX
was established by array-CGH analysis; some genetic
alterations were found and maintained from PR to
PDX. Some of these regions, in particular the loss of
3p, 6p, 8p, 9p, and 14q regions and the gain of 3q,
and 20q regions, are common with the previously
found by Miller and coll. in an ICC case series [40].
Other genetic alterations were found only in PDX;
this could suggest that, even if the PDX retained the
main characteristics of primary tumor, i) the murine
environment leads to the acquirement of further
chromosomic alterations, ii) the tumor experiences
progression regardless of recipient and acquires new
chromosomal aberrations, as previously demonstrated
by Shiraishi and collaborators [41], iii) the more ag-
gressive cell subpopulation is selected in the murine
model.
Comparing transcriptomic profiling of primitive tumor
and its PDX, we found a high correlation in terms of
gene and microRNA expression, demonstrating that the
PDX retained most of primary tumor genetic character-
istics. To further characterize our model, we identified a
panel of deregulated genes comparing both PR and PDX
tumor with published normal bile duct epithelia; to over-
come the lack of normal samples in our Institution, we
used external dataset of normal biliary tissues, even
introducing a possible bias. We select a panel of down-
regulated genes involved in blood coagulation, inflam-
mation response, and in lipid metabolism processes and
a panel of up-regulated genes involved in DNA biosyn-
thesis processes. We also selected a panel of twenty-eight
microRNAs (7 down-regulated and 21 up-regulated), most
of them involved in the cell cycle, apoptosis, migration
and proliferation regulation. In particular, we found an
up-regulation of miR-21, already described in CCA; in
fact, the mir-21 overexpression is typical of ICC
compared to both normal tissues and hepatic cancer
[42, 43]. Moreover, functional studies on CCA cell
lines showed the potential oncogenic role of miR-21 by
inhibiting PDCD4 and TIMP3, involved in apoptosis
and in the inhibition of the matrix metalloproteinases,
respectively [44].
Conclusions
In conclusion, in this study we firstly established an ICC
PDX model and characterized it for genetic and molecu-
lar alterations; we demonstrated that this model recapit-
ulates the histological characteristics and maintains most
of the genetic features of primary tumor, providing a re-
liable tool to study this neoplasia and to test the efficacy
of new drug.
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